Golden Helix Expands Copy Number Collaboration Program; Signs Five Additional Institutions
News Jun 25, 2008
Golden Helix, Inc. has expanded its collaboration program to refine and advance the science of copy number analysis. The company recently signed five additional academic institutions to the program, bringing the total to 11.
Those added include Imperial College London, University of Edinburgh, University of Alabama at Birmingham, University Hospital of Schleswig-Holstein (Kiel, Germany) and The Hospital for Sick Children (Toronto, Canada).
“Gaining a better understanding of copy number variation is critical to understanding human disease,” said Stephen Scherer, Director of The Centre for Applied Genomics at The Hospital for Sick Children and Professor of Molecular Genetics at the University of Toronto, a leading scientist in the copy number variation field.
“Golden Helix is making extraordinary progress in terms of providing tools to analyze this data, especially in the context of whole genome association studies. The sheer size, complexity, and novelty of these studies present numerous challenges, and it will take collaborative efforts such as this one to maximize the opportunity for success.”
Altogether, the collaborations cover a diverse set of diseases and sample characteristics as well as data generated from multiple Illumina and Affymetrix genotyping platforms.
According to the agreement, Golden Helix will provide data processing, quality control, analysis, and consulting services in exchange for the purchase of its software and feedback to help improve its products and services.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE